Clinical trial · Interventional
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
Acupuncture for Chemo-Induced Peripheral Neuropathy (CIPN) in Multiple Myeloma (MM) Patients- A Randomized Controlled Trial
NCT04770402CI-TRIAL-00085110terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual
Summary
Brief summary (as posted)
This randomized, controlled trial is designed to evaluate the effect of acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN), other symptoms, and potential opioid and concomitant medication sparing effects in comparison to standard of care management in Multiple Myeloma subjects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy-induced Peripheral Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture | Other | — | UNRESOLVED |
| Standard of Care CIPN management | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Acupuncture
- description
- Subjects on this arm will receive 12 sessions of acupuncture over approximately 10 weeks, along with continued standard treatment by their physician.
- interventionNames
- Other: Acupuncture
- type
- ACTIVE_COMPARATOR
- label
- Standard of Care
- description
- Subjects on this arm will not receive acupuncture, but will continue to be followed by their physician with standard treatment for their neuropathy.
- interventionNames
- Other: Standard of Care CIPN management
Primary outcomes (1)
- measure
- Change of Neuropathy in Actively Treated Multiple Myeloma Subjects Diagnosed With Chemotherapy-induced Peripheral Neuropathy Who Received Acupuncture vs Standard of Care Management.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Age ≥ 18 years at the time of consent 3. Subject has diagnosis of Multiple Myeloma (any stage) per Investigator 4. Currently being treated with bortezomib or bortezomib-combination chemotherapy 5. ECOG Performance status of 0-3 6. Life expectancy of ≥ 12 weeks 7. Chemotherapy-Induced Peripheral Neuropathy score of ≥ 2 8. No planned hospital admission in the next 10 weeks 9. As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study Exclusion Criteria: 1. Uncontrolled intercurrent illness/medical condition or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator 2. Subjects with neuropathy pain as a result of spinal injury or vertebral compression fractures 3. Subjects with needle phobia 4. Previous diagnosis of amyloidosis or POEMS syndrome 5. Local infection at or near the planned acupuncture sites (see Appendix A) 6. Subjects with metastatic involvement of the nervous system/active central nervous system disease 7. Plan to receive Healing Touch or Oncology Massage during study 8. Have received acupuncture within 30 days prior to enrollment
References
Publications (0)
Data not yet available
No reference posted for this study.